Recurrent Malignant Solid Neoplasm Clinical Trials

15 recruiting

Recurrent Malignant Solid Neoplasm Trials at a Glance

15 actively recruiting trials for recurrent malignant solid neoplasm are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Seattle. Lead sponsors running recurrent malignant solid neoplasm studies include Children's Oncology Group, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse recurrent malignant solid neoplasm trials by phase

Treatments under study

About Recurrent Malignant Solid Neoplasm Clinical Trials

Looking for clinical trials for Recurrent Malignant Solid Neoplasm? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Malignant Solid Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Malignant Solid Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)70 enrolled185 locationsNCT06126276
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center111 enrolled1 locationNCT04693468
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Hematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+1 more
National Cancer Institute LAO5,000 enrolled140 locationsNCT02474160
Recruiting
Phase 1Phase 2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Lymphoma+7 more
Children's Oncology Group63 enrolled34 locationsNCT04870944
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Childhood Malignant Solid Neoplasm+6 more
Children's Oncology Group81 enrolled20 locationsNCT06620302
Recruiting
Not Applicable

Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
M.D. Anderson Cancer Center120 enrolled1 locationNCT05059678
Recruiting
Phase 1Phase 2

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
OHSU Knight Cancer Institute38 enrolled1 locationNCT06320405
Recruiting
Phase 1Phase 2

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm+3 more
Tianhong Li77 enrolled1 locationNCT05101356
Recruiting
Phase 2

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Metastatic Malignant Solid NeoplasmRecurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8+17 more
Rutgers, The State University of New Jersey40 enrolled2 locationsNCT03428802